ZGNX News and Press, Zogenix Inc. From 11/11/19

Image source: The Motley Fool. Zogenix Inc   (NASDAQ: ZGNX) Q3 2019 Earnings Call Nov 7, 2019 , 4:30 p.m. ET Operator Continue reading

Zogenix, Inc. (ZGNX) Q3 2019 Earnings Conference Call November 7, 2019 04:30 pm ET Company Participants Brian Ritchie - LifeSci Advisors, IR Steve Farr - President, Chief Executive Officer Mike Smith - Executive Vice President, Chief Financial Officer, Treasurer and Secretary G...

Zogenix (NASDAQ: ZGNX ): Q3 GAAP EPS of -$6.75 misses by $5.73 . Revenue of $0.63M beats by $0.24M . Press Release More news on: Zogenix, Inc., Earnings news and commentary, Healthcare stocks news,

Resubmitted NDA for FINTEPLA® for the treatment of Dravet syndrome Enrollment completed for FINTEPLA global Phase 3 trial in Lennox Gastaut syndrome; top-line data anticipated in Q1 2020 Acquired Modis Therapeutics, Inc.; adding MT1621, a proprietary, late-stage in...

Zogenix (NASDAQ: ZGNX ) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close. The consensus EPS Estimate is -$1.04 (+3.7% Y/Y) and the consensus Revenue Estimate is $0.39M Over the last 2 years, zgnx has beaten EPS estimates 25% of the time and h...

EMERYVILLE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2019, after the market close, an...

Data have shown long-term, clinically meaningful convulsive seizure reduction (75.5%; p<0.001) in Dravet syndrome patients under 6 years old, as well as clinically meaningful and profound reduction in high-risk tonic-clonic seizures in Phase 3 study patients Data from Phase 1 stu...

Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating and $43 (110% upside) price target at Barclays. More news on: Axonics Modulation Technologies, Inc., GW Pharmaceuticals plc, ShockWave Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more...

EMERYVILLE, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced that five posters related to its investigational therapy, FINTEPLA ® (ZX008, fenfluramine oral solution), will be presented ...

Safety and efficacy data from a global, retrospective Phase 2 study (RETRO) support potential for deoxynucleoside substrate enhancement therapy (SET) to treat TK2 deficiency, an often-fatal mitochondrial DNA depletion disorder Highly significant impact on survival probability (p<0.00...